Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
297.45B
Market cap297.45B
Price-Earnings ratio
16.52
Price-Earnings ratio16.52
Dividend yield
2.73%
Dividend yield2.73%
Average volume
11.48M
Average volume11.48M
High today
$121.25
High today$121.25
Low today
$118.40
Low today$118.40
Open price
$119.39
Open price$119.39
Volume
10.71M
Volume10.71M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

As of today, Merck(MRK) shares are valued at $120.00. The company's market cap stands at 297.45B, with a P/E ratio of 16.52 and a dividend yield of 2.7%.

As of 2026-04-01, Merck(MRK) stock has fluctuated between $118.40 and $121.25. The current price stands at $120.00, placing the stock +1.4% above today's low and -1.0% off the high.

The Merck(MRK)'s current trading volume is 10.71M, compared to an average daily volume of 11.48M.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $125.14 at its peak.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $125.14 at its peak.

MRK News

Investor's Business Daily 15h
Dow Jones Drug Giant Merck, Costco Approach New Buy Points

Stocks Near A Buy Zone Dow Jones Drug Giant Merck, Costco Approach New Buy Points Licensing As the Dow Jones Industrial Average and other stock indexes traded h...

Dow Jones Drug Giant Merck, Costco Approach New Buy Points
Nasdaq 18h
Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc (Symbol: MRK) is the #8 broker pick, on average, out of the 30 stocks makin...

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick
Simply Wall St 1d
Merck Cardiovascular Readouts Point To New Growth Drivers Beyond Oncology

Merck (NYSE:MRK) reported positive Phase 3 results for its oral PCSK9 inhibitor, enlicitide decanoate, showing marked LDL C reduction and a favorable safety pro...

Merck Cardiovascular Readouts Point To New Growth Drivers Beyond Oncology

Analyst ratings

63%

of 30 ratings
Buy
63.3%
Hold
36.7%
Sell
0%

More MRK News

TipRanks 2d
Terns Pharmaceuticals downgraded to Hold from Buy at Truist

Truist analyst Srikripa Devarakonda downgraded Terns Pharmaceuticals (TERN) to Hold from Buy with a price target of $53, down from $56, after the company agreed...

TipRanks 2d
Merck announces results from CORALreef AddOn study of enlicitide decanoate

Merck (MRK) announced detailed results from CORALreef AddOn, an active comparator study designed to evaluate the efficacy and safety of enlicitide decanoate com...

Investor's Business Daily 2d
How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'

Technology How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle' Licensing Merck's (MRK) experimental cholesterol buster easily out...

How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'
Nasdaq 3d
Merck's WINREVAIR Phase 2 CADENCE Trial Shows Positive Proof-of-Concept In Pulmonary Hypertension

(RTTNews) - Merck (MRK) announced detailed results from the Phase 2 CADENCE study, which evaluated the efficacy, safety, and tolerability of two doses (0.3 mg/k...

Merck's WINREVAIR Phase 2 CADENCE Trial Shows Positive Proof-of-Concept In Pulmonary Hypertension
Simply Wall St 3d
Assessing Merck Valuation After Mixed Recent Returns And Keytruda Patent Uncertainty

Merck (MRK) has drawn attention after recent share price moves, with the stock showing mixed short term performance while still reflecting longer term gains tha...

Assessing Merck Valuation After Mixed Recent Returns And Keytruda Patent Uncertainty
The Motley Fool 4d
Enliven Theraeutics' Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN 1.17%), reported the exercise of 40,000 stock options for Common Stock and immediate s...

Enliven Theraeutics' Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Simply Wall St 6d
Is It Too Late To Consider Merck After Recent 40% One Year Rally?

Wondering if Merck at around US$119 per share still offers value, or if most of the upside is already reflected in the price? This article walks through the key...

Is It Too Late To Consider Merck After Recent 40% One Year Rally?

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.